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Cystic craniopharyngioma
Intratumoral chemotherapy with alpha interferon
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ABSTRACT
Objective: To assess whether the cystic craniopharyngiomas can be controlled with the 
use of intratumoral applications of interferon alpha. Method: Nineteen patients with the 
diagnosis of cystic craniopharyngioma were treated with intratumoral chemotherapy with 
interferon alpha from January 2002 to April 2006. All patients underwent placement of 
an intracystic catheter connected to an Ommaya reservoir. Through this reservoir were 
made applications during chemotherapy cycles. Each cycle corresponded to application 
of 3,000,000 units of interferon alpha three times per week on alternate days totalizing 
36,000,000 units. Response to treatment was evaluated by calculating the tumor volume 
on MRI control after one, three and six months after the end of each cycle. Patients who 
developed worsening of symptoms or who had insignificant reduction in tumor volume 
during follow-up underwent repeat cycle chemotherapy. Results: Four patients received 
four cycles of chemotherapy, three patients received three cycles, six patients received 
two cycles and six patients received one. The lower percentage of reduction in tumor 
volume was 60% and the bigger reduction was 98.37%. Eleven patients had a reduction 
greater than 90%. Five patients had a tumor reduction between 75 and 90% and in three 
patients the tumors were reduced by less than 75%. No deaths occurred during treatment 
and side effects of interferon alpha were well tolerated. No treatment was discontinued. 
Follow-up after the last application ranged from one year and five months to three years 
and nine months. Conclusion: The intratumoral chemotherapy with interferon alpha 
decreases the volume of cystic craniopharyngiomas and so far can be considered a new 
therapeutic alternative. 
Key words: cystic craniopharyngioma, interferon alpha, intratumoral chemotherapy, 
bleomycin, Ommaya reservoir.
Craniofaringioma cístico: quimioterapia intratumoral com interferon alfa
RESUMO
Objetivo: Avaliar se os craniofaringiomas císticos podem ser controlados com aplicações 
intratumorais de interferon alfa. Método: De janeiro de 2002 a abril de 2006, 19 pacientes 
foram submetidos à colocação de um cateter intracístico conectado a reservatório 
de Ommaya para aplicações intratumorais de ciclos de 36.000.000 de unidades de 
interferon alfa. A resposta ao tratamento foi avaliada pelo cálculo do volume tumoral na 
ressonância magnética de controle ao término de cada ciclo. Resultados: Os pacientes 
receberam de um a quatro ciclos de quimioterapia. Onze pacientes apresentaram uma 
redução do volume tumoral maior que 90%; cinco pacientes apresentaram uma redução 
entre 75% e 90% e três pacientes uma redução menor de 75%. Não houve óbitos durante 
o tratamento e os efeitos colaterais do inferferon alfa foram bem tolerados. Nenhum 
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tratamento foi interrompido. Conclusão: A quimioterapia intratumoral com interferon 
alfa diminui o volume dos craniofaringeomas císticos e pode ser considerada uma nova 
alternativa terapêutica. 
Palavras-chave: craniofaringioma cístico, interferon alfa, quimioterapia intratumoral, 
bleomicina, reservatório de Ommaya.
Craniopharyngiomas account for 1.2% to 4% of all 
brain tumors and 6 to 9% of all childhood tumors1. They 
are the most common non-glial tumors in childhood2 and 
originate from the embryonic remains of squamous cells 
through the hypophyseal-pharyngeal duct.
Complete resection is often impossible without signif-
icant morbidity due to the proximity of the tumor to im-
portant brain structures, such as the optic chiasm, third 
cranial nerve, hypothalamus and internal carotid artery, 
which constitute obstacles during surgical manipulation. 
The mortality rate ranges from 11 to 42%. Even after com-
plete macroscopic resection, the craniopharyngioma re-
currence rate ranges from 23 to 50%3.
Permanent harmful effects on behavior, learning and 
endocrine function after surgery with or without subse-
quent radiotherapy are common and may be devastat-
ing. There are frequent fluctuations in sodium level in the 
postoperative period such that patients at times exhibit 
diabetes insipidus and at other times inappropriate se-
cretion of antidiuretic hormone, progressing with either 
hypernatremia or hyponatremia that is difficult to con-
trol and may lead to severe brain damage or even death. 
Patients may also exhibit hyperphagia, obesity, low stat-
ure and psychiatric disorders in the later postoperative 
period1,2,4.
There is no consensus in the literature on the best 
way to treat an adamantinomatous craniopharyngioma 
in childhood. Intratumoral chemotherapy with bleomy-
cin or the intracystic application of radiopharmacologi-
cal agents may control these tumors, but numerous side 
effects have been described5. 
The aim of the present study was to determine wheth-
er the intracystic use of alpha interferon reduces and/
or controls the volume of these craniopharyngiomas and 
whether this chemotherapy may be considered a novel 
treatment alternative.
METHOD
The research project and consent form were analyzed 
and approved by the Ethics Committee of the university 
hospital of the Universidade Federal de São Paulo/Escola 
Paulista de Medicina (São Paulo, Brazil).
Between January 2002 and April 2006, 19 patients di-
agnosed with cystic craniopharyngioma were treated with 
intratumoral chemotherapy with alpha interferon at the 
Neurooncology Unit of the Pediatric Oncology Institute 
of the Universidade Federal de São Paulo. Sixteen patients 
were male and three were female. Mean age was 11 years 
(minimum=one year 10 months; maximum=19 years).
Predominantly cystic craniopharyngiomas were con-
sidered those in which the cystic portion accounted for 
at least 60% of the tumor. This diagnosis was made using 
computed tomography and/or magnetic resonance im-
aging (MRI) of the cranium. 
In the initial clinical condition, seven patients com-
plained of headaches, three had vision loss, seven had low 
stature and two exhibited signs and symptoms of severe 
intracranial hypertension. Fourteen patients had not un-
dergone any past treatment and five had been submitted 
to surgical resection, followed by recurrence of the tumor.
All patients underwent the implantation of an intra-
tumoral silicone catheter connected to an Ommaya res-
ervoir (HP®) and attached in the subgaleal space. Fifteen 
patients underwent frontal craniotomy for subfrontal, mi-
crosurgical access to the cyst. Three patients with non-
hypertensive hydrocephalia underwent fenestration of 
the cyst and the placement of the catheter through neu-
roendoscopy. In one patient with an extensive cystic tu-
mor measuring 7.7×5.6×6 cm3 and compromising the en-
tire right frontal lobe, the catheter was installed by direct 
puncture through an orifice in the right frontal trepana-
tion (Fig 1A). 
Tumor volume was calculated in the preoperative pe-
riod as well as at one and six months following the end 
of treatment with RMI, using the measurements of the 
three largest axes. This value was multiplied by a correc-
tion factor of 0.52 due to the elliptical shape6. 
Fifteen days after surgery was considered the ideal 
time to begin the applications. The administration of al-
pha interferon was performed in a clinic setting under 
rigorous antisepsis three times a week on alternating days 
for one month (12 applications). One hour prior to each 
procedure, an anesthetic pomade (Enla®) was applied to 
the scalp above the Ommaya reservoir. Each application 
consisted of an injection of 3,000,000 units of alpha in-
terferon, totaling 36,000,000 units, which was considered 
one treatment cycle.
After antisepsis, the puncture of the reservoir was 
performed with slow, delicate aspiration of the intracys-
tic fluid. The volume to be aspirated prior to the injection 
of the drug was determined by the moment at which the 
patient began to complain of a headache of moderate in-
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tensity, thereby avoiding the complete emptying of the 
cyst. One milliliter (ml) was the total volume of interfer-
on injected. In order to achieve an adequate mixture of 
the drug and tumor fluid, further aspiration and re-in-
jection of the drug/fluid mixture was performed slow-
ly three times.
Control MRI of the cranium was performed at one, 
three and six months following the end of each cycle. Pa-
tients who demonstrated an important reduction in tu-
mor size in these first six months continued to undergo 
MRI control every six months. Patients who progressed 
with a worsening of symptoms or either an increase or 
insignificant reduction in tumor size underwent an ad-
ditional treatment cycle, repeating the same sequence of 
intervals in the control imaging exam. 
RESULTS
The number of cycles to which each patient was sub-
mitted varied in accordance to the response of the cra-
niopharyngioma to chemotherapy with alpha interfer-
on (Table 1). The Kruskall-Wallis test was used to de-
termine whether the number of cycles affected the tu-
mor response, revealing no statistically significant differ-
ence in the reduction of tumor volume between cycles. 
The minimal interval between cycles was one month and 
the maximal interval was two year five months (mean= 
6.12 months).
The follow-up period after the last application ranged 
from one year five months to three years nine months 
(mean=22 months). The total follow-up period from the 
placement of the catheter until June 2007 ranged from 
one year six months to five years (mean=3 years). 
Table 2 displays the pretreatment and post-treatment 
tumor volume. The non-parametric Wilcoxon test for two 
non-independent samples was used to determine differ-
ences between initial and final volume measurements and 
revealed a statistically significant reduction in tumor vol-
ume (p=0.000). Figures 1A-B and 2A-2B display examples 
of control images taken during diagnosis and six months 
after the end of treatment.
During treatment, no patient progressed with a se-
vere clinical aggravation that would indicate the inter-
ruption of the treatment or the use of conventional sur-
gical treatment. Only one patient experienced greater vi-
sion impairment during treatment, which improved af-
Fig 1. [A] Case 16: Craniopharyngioma with a large cystic compo-
nent time of diagnosis; [B] Case 16: Two year follow-up after the 
last chemotherapy cycle.
Table 1. Number of cycles. Mean reduction in tumor volume and 
statistical result.
Total number 
of cycles
Number of 
patients
Tumor 
reduction (%)
Kruskal-
Wallis test
1 6 87.15
c2calc=2.053
2 6 92.16
3 3 83.51
4 4 86.13
Table 2. Tumor volume at diagnosis and six months after last 
treatment cycle and individual percentage of cyst reduction.
Patient Initial size (cm3) Final size (cm3) Reduction (%)
1 23.29 2.98 87.20
2 54.08 4.69 91.32
3 35.04 0.81 97.68
4 37.44 2.63 92.97
5 12.87 1.71 86.71
6 7.02 2.08 70.37
7 39.0 15.6 60.0
8 3.36 0.14 95.83
9 9.79 0.94 90.39
10 34.94 1.06 96.96
11 40.32 4.65 88.46
12 52.32 3.57 93.17
13 25.74 4.8 81.35
14 23.29 3.37 85.53
15 16.38 1.06 93.52
16 134.53 2.18 98.37
17 7.97 2.2 72.39
18 45.13 2.53 94.39
19 34.03 1.94 94.29
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ter aspiration of the cyst followed by injection with al-
pha interferon. Four patients who further complained of 
headaches became asymptomatic after further treatment 
with applications of alpha interferon. The 14 remaining 
patients underwent further treatment cycles due to per-
sistence of the cyst or its return to the initial dimensions.
Table 3 displays the data on the patients regarding age, 
gender, previous treatment, catheter installation method, 
number of cycles, total dose administered, initial and fi-
nal measurements, reduction rates, follow-up time and 
side effects.
DISCUSSION
The main objective of treatment for craniopharyngi-
oma has always been the removal of the greatest possible 
amount of the tumor in order to minimize the risk of re-
currence. This resection should be accompanied by no or 
minimal functional loss, which is all the more important 
in children, as the inherent risks of surgical treatment are 
more substantial in this population.
Most craniopharyngiomas that develop in childhood 
have characteristics that distinguish them from cranio-
pharyngiomas diagnosed in adulthood, which makes their 
management more difficult. Indeed, childhood cranio-
pharyngiomas are larger and more difficult to remove 
completely7. In children, cysts are present in 90% of all 
craniopharyngiomas. The adamantinomatous variant is 
prevalent, whereas the papillary or mixed type is rare. 
Fig 2. [A-B] Case 3: Bilobate craniopharyngioma and 3-year follow-
up after intratumoral chemotherapy.
Table 3. Distribution of 19 patients regarding, age, gender, previous treatment, surgery, number of alpha interferon cycles, total dose (unit), 
initial and final volume (unit), reduction, follow-up and side effects.
Case Age Sex
Previous 
trmt Surgery Cycles Total dose
Inicial 
size
Final 
size Reduction
Follow-
up Side effects
1 18 y F yes craniotomy 3 108,000,000 23.29  2.98 87.2% 21 m headache
2 7y 11m M yes craniotomy 2 72,000,000 54.08 4.69 91.32% 20 m headache/fever
3 1y 10 m M no craniotomy 4 144,000,000 35.04 0.81 97.68% 22 m headache/fever
4 12y 8m M no craniotomy 3 108,000,000 37.44 2.63 92.97% 45 m depression/chronic 
fatigue syndrome
5 13y 5 m M no craniotomy 2 72,000,000 12.87 1.71 86.71% 26 m headache/fever
6 10y M yes craniotomy 3 108,000,000 7.02 2.08 70.37% 17 m headache
7 7y F yes craniotomy 4 144,000,000 39 15.6 60% 20 m headache/ eyelid 
erythema
8 6 y M no craniotomy 2 72,000,000 3.36 0.14 95.83% 20 m fever
9 10y 6m M no craniotomy 2 72,000,000 9.79 0.94 90.39% 2y 4m headache/fever
10 12y 2m M no craniotomy 1 36,000,000 34.94 1.06 96.96% 2y 3m fever/ eyelid 
erythema
11 11y F no craniotomy 4 144,000,000 40.32 4.65 88.46% 20 m headache
12 12y 9 m M no craniotomy 1 36,000,000 52.32 3.57 93.17% 22 m headache
13 19y 2m M no neuroendoscopy 1 36,000,000 25.74 4.8 81.35% 23 m headache/fever/
eyelid erythema
14 12y 4m M no craniotomy 1 36,000,000 23.29 3.37 85.53% 17 m NDN
15 19y M no endoscopia 1 36,000,000 16.38 1.06 93.52% 17 m headache
16 3y 7m M no puncture 4 144,000,000 134.53 2.18 98.37% 24 m headache/fever/
eyelid erythema
17 15y 4m M yes craniotomy 1 36,000,000 7.97 2.2 72.39% 21 m headache
18 7y 9m M no neuroendoscopia 2 36,000,000 45.13 2.53 94.39% 22 m
19 18y M no craniotomy 2 36,000,000 34.03 1.94 94.29% 20 m headache
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Even after complete surgical removal, the incidence of re-
currence is also high among children3,7,8. The retrochias-
matic variant, which is associated to significant impair-
ment of the hypothalamus, accounts for approximately 
50% of cases, whereas the purely intrasellar type is rare. 
Thirty percent of patients exhibit associated obstructive 
hydrocephalia. The reason for this complex behavior in 
childhood has not yet been fully clarified, but the early 
clinical manifestation of a tumor known to be of a con-
genital nature is believed to be related to more aggressive 
biological behavior3,7.
According to reports from pediatric series and stud-
ies on mixed populations of patients, the lower rate of 
complete resections in children in comparison to adults 
demonstrates that technical difficulties are truly greater 
in the child population. Moreover, the postoperative pe-
riod is particularly complex, especially with regard to the 
hydroelectrolytic balance and sudden fluctuations in na-
tremic levels, which are difficult to control. Craniopha-
ryngioma resection may cause hormonal deficiencies and 
vision impairment related to the location of the tumor. In 
the follow up of these children, there are reports of mor-
bid obesity and alterations in complex cortex functions, 
such as memory and behavior, as well as learning dis-
abilities9-11. The combination of these conditions severe-
ly compromises the quality of life of these children. Pa-
tients with craniopharyngioma have considerably lower 
quality of life indexes in comparison to healthy children 
and their social relations and emotional development are 
affected in a catastrophic manner, as craniopharyngio-
mas are mainly diagnosed in children at school ages12,13.
All these considerations justify the enormous inter-
est in the proposal of novel treatment modalities for cra-
niopharyngiomas in children. The use of bleomycin was 
an effort to encounter a novel strategy for improving the 
results of craniopharyngioma treatment14. Bleomycin is 
particularly effective in the treatment of squamous cell 
carcinoma. It is believed that squamous cell carcino-
ma and craniopharyngioma have the same embryolog-
ical origin and, thus, the use of bleomycin in the treat-
ment of craniopharyngiomas has also achieved good re-
sults. However, bleomycin is a highly neurotoxic drug 
and severe complications may arise following its leak-
age through the walls of the cyst, which can even lead to 
death15. Such risk associated to a control of approximately 
41% of cases submitted to this treatment16 has led to the 
gradual disuse of bleomycin, which is currently only in-
dicated for exceptional cases and recurrences.
In this context, alpha interferon emerges as a quite 
promising therapy, as it does not have the neurotoxic ef-
fects found with bleomycin. The antitumoral activity of 
interferons is due to their anti-proliferation, cytotoxic and 
maturational effects, with the simultaneous modulation 
in patient immune response. Interferons are glycopro-
teins pertaining to the cytokine family and are related to 
cell growth factor beta and tumor necrosis factor, which 
are responsible for the control of cell differentiation and 
proliferation17.
The efficacy of alpha interferon is well established re-
garding its activity against squamous cell carcinoma of 
the skin, in which it induces apoptosis18. Ikiċ et al.19,20 
were the first to use the intratumoral application in the 
treatment of squamous cell carcinoma, demonstrating a 
reduction and even disappearance of this tumor. 
Jakacki et al.21 were the first to use systemic alpha inter-
feron in the treatment of recurring craniopharyngiomas 
and those that did not respond to conventional treatment. 
Based on the fact that craniopharyngiomas and squamous 
cell carcinomas have the same embryological origin and 
that squamous epithelium is characteristically found in 
both the cyst wall and solid component of the craniopha-
ryngioma, a phase II study was carried out on a group of 
15 patients between 4.2 and 19.8 years of age. Three pa-
tients who demonstrated a complete response (defined as 
the complete radiological disappearance of the tumor) had 
had predominantly cystic tumors. In the study, all patients 
experienced episodes of fever in the first weeks of treat-
ment, accompanied by muscle cramps and myalgia. Sev-
en patients developed important signs and symptoms of 
alpha interferon toxicity, which led to either the interrup-
tion of treatment or a reduction in the doses administered. 
In 2002, Chamberlain22 was the first to use an intra-
ventricular application of alpha interferon for the treat-
ment of neoplastic meningitis. The manifestations of neu-
rotoxicity (described mainly as chronic fatigue syndrome) 
were easily treated and did not impede the continuation 
of treatment.
In the present study, 3,000,000 units of alpha inter-
feron were administered to the interior of the cyst three 
times a week for four weeks, empirically. Moreover, the 
administration pathway has not been previously used and 
was justified by the possibility of administering a greater 
concentration of the drug in the interior of the cyst and, 
consequently, a greater and more prolonged exposed of 
the tumor cells to the action of the agent. The authors 
found no reports in the literature on the intratumoral ad-
ministration of alpha interferon in brain tumors or in-
tracystic administration in cases of craniopharyngiomas. 
This type of therapy was based on the authors’ previous 
experience with the treatment of craniopharyngiomas us-
ing bleomycin14,23. 
The need for the administration of new cycles was es-
tablished based on the clinical or radiological response of 
the tumor. Moreover, the Kruskall-Wallis test revealed no 
differences in the reduction of tumor volume in relation 
to total number of cycles administered. 
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All patients (100%) experienced an important reduc-
tion in tumor volume at the end of treatment. The mean 
initial volume was 33.50 cm3 and mean final volume was 
3.10 cm3. The reduction in tumor volume was greater 
than 90% in eleven patients (57.89%), between 81 and 87% 
in five patients (26.31%) and only three patients (15.78%) 
had less important reductions in tumor volume, but these 
reductions were still 60, 70 and 72%. The variability in re-
sponse suggests the individual susceptibility of each pa-
tient, whether related to the characteristics of each tumor 
or the immune system of each patient. 
The fluid aspirated at different times in the chemo-
therapy cycle was analyzed to determine whether the vol-
ume of the tumors was actually controlled by the succes-
sive mechanical aspirations. In 2007, the authors24 pub-
lished the results of the analyses of tumor necrosis fac-
tor-related apoptosis in the different samples of intracys-
tic fluid, demonstrating the alpha interferon indeed plays 
an important role in the induction of apoptosis through a 
non-mitochondrial pathway in craniopharyngioma cells, 
leading to cell death24. The degree of apoptosis mediat-
ed by the FAS-ligand is only one of the factors of apopto-
sis24. Other non-mitochondrial apoptosis pathways me-
diated by caspases are currently under study. 
The literature states that fatigue is the most frequent 
side effect22 and main limiting factor to treatment with al-
pha interferon. In the present study, however, headache 
was the most frequent symptom. No patient needed to 
interrupt the treatment and, although no hormonal def-
icit was added to the preexisting deficits, one patient de-
veloped diabetes insipidus after the installation of the in-
tratumoral catheter.
The most important aspect in the adoption of this 
treatment is the change in strategies established for the 
treatment of cystic craniopharyngiomas in childhood. Pa-
tients with craniopharyngioma live with a chronic disease 
and are subject to periods of intensified symptoms or de-
terioration that could be treated with the application of 
intratumoral alpha interferon. Provided these children ex-
perience improved vision, recover normal hormone levels, 
grow normally, attend school, exhibit adequate cognitive 
performance and neuropsychomotor development with 
minimal or no impairment to quality of life in this impor-
tant age group, a further application of the chemothera-
py cycle is believed to be less aggressive than an addition-
al surgical intervention or sessions of radiotherapy. How-
ever, as this is a new treatment modality, a greater follow 
up time is needed to assess the effectiveness of alpha in-
terferon in the long-term control of craniopharyngioma. 
Health care professionals in charge of the treatment of 
childhood craniopharyngioma should be familiar with all 
forms of treatment and should demonstrate considerable 
skill in conducting different treatment modalities in order 
to provide better quality of life to patients, selecting the 
most adequate individualized option in each specific case. 
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